Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Author's Avatar
Nov 10, 2022

- Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumors towards Phase 1 clinical development
- Ended the quarter with $13.8 million of cash expected to fund operations and drive expanded pipeline development forward